Orthopedics Articles

Orthopedics

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Dolores Shoback, - Considerable progress has been made in the development and testing of agents to treat osteoporosis. Most impressive are reports on new antiresorptive agents—both bisphosphonates (ibandronate and zoledronic acid) and monoclonal antibodies

Related Articles

Emergency Management of Inherited Metabolic Disorders
Topics in Clinical Nutrition, 11/16/09    Relevance Score: 69%

Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: A prospective study
Osteoporosis International, 11/30/09    Relevance Score: 68%

Cortical neurochemistry in euthymic patients with bipolar I disorder
World Journal of Biological Psychiatry, 11/25/09    Relevance Score: 67%

Roles of the lipid peroxidation product 4-hydroxynonenal in obesity, the metabolic syndrome, and associated vascular and neurodegenerative disorders
Experimental Gerontology, 11/12/09    Relevance Score: 67%

Paget's disease of bone
Expert Review of Endocrinology & Metabolism, 11/10/09    Relevance Score: 67%

Today in Bone Metabolism...keeping you current

The efficacy of calcitriol therapy in the management of bone loss and fractures: A qualitative review
Osteoporosis International, 12/09/09

Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: Systematic review and meta-analysis
Osteoporosis International, 12/09/09

Anemia and the risk of non-vertebral fractures: The Tromsø Study
Osteoporosis International, 12/09/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address